Replies to post #219267 on Biotech Values

[ghmm]

Should note the preclinical poster (RCC and colon) is NOT in the indication of the Phase 2 (2nd line Melanoma)

[DewDiligence]

SNDX 9% drop today apparently due to NKTR tie-in, as least in part.

[DewDiligence]

(SNDX)—NKTR-214 + Entinostat phase-1/2 trial in melanoma never even started:

https://www.sec.gov/Archives/edgar/data/1395937/000156459019006772/sndx-10k_20181231.htm

In January 2019, we agreed with Nektar not to advance the proposed clinical trial and the parties terminated the agreement. There were no costs associated with terminating the agreement.

h/t @bio_clouseau.